{"nctId":"NCT00443846","briefTitle":"RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)","startDateStruct":{"date":"2007-02-13","type":"ACTUAL"},"conditions":["Meningitis, Meningococcal","Rotavirus Infections"],"count":247,"armGroups":[{"label":"Group 1: Concomitant Administration","type":"EXPERIMENTAL","interventionNames":["Biological: RotaTeq®","Biological: NeisVac-C®"]},{"label":"Group 2: Sequential Administration","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: RotaTeq®","Biological: NeisVac-C®"]}],"interventions":[{"name":"RotaTeq®","otherNames":["V260"]},{"name":"NeisVac-C®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy infants, aged from 6 weeks through full 7 weeks,\n* Consent form signed by at least one parent or by the legal representative properly informed about the study,\n* Parent(s) / legal representative able to understand the protocol requirements and to fill in the Diary Card.\n\nExclusion Criteria:\n\n* History of congenital abdominal disorders, congenital malformation of the gastrointestinal tract that could predispose to intussusception, or abdominal surgery,\n* Congenital fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency,\n* Known or suspected impairment of immunological function,\n* Known hypersensitivity to any component of RotaTeq® (e.g. sucrose) or of NeisVac-C® (including tetanus toxoid),\n* Prior administration of any rotavirus vaccine,\n* Prior administration of any vaccine within the 28 days prior to randomisation,\n* Fever (rectal temperature ≥38.1°C) and/or acute diarrhoea and/or vomiting at randomisation,\n* History of known prior rotavirus gastroenteritis, chronic diarrhoea, or failure to thrive,\n* Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection,\n* Clinical evidence of active gastrointestinal illness,\n* Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 14 days prior to randomisation. Note: Infants on inhaled and/or topical steroids may participate in the study,\n* Infants residing in a household with an immunocompromised person,\n* Prior receipt of a blood transfusion or blood products, including immunoglobulins.","healthyVolunteers":true,"sex":"ALL","minimumAge":"42 Days","maximumAge":"55 Days","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Seroresponse for Meningiococcal Group C Serotype","description":"Antibody seroprotection to meningiococcal Group C serotype was measured by serum bactericidal antibody with rabbit complement (sRBA). The criterion for seroresponse was an sRBA titer \\>=1:8.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":116},"commonTop":["Irritability","Diarrhoea","Pyrexia","Vomiting","Injection-site erythema"]}}}